Stealth BioTherapeutics Corp (MITO) Stock
MITO is no longer traded. Stealth BioTherapeutics was delisted from the Nasdaq in November 2022.
Prices on this page are historical; the last trade was November 15, 2022 at $0.32.
Stealth BioTherapeutics stock price history
MITO final trading statistics
- Final close
- $0.32
- Final trading day
- Nov 15, 2022
- Market cap at delisting
- $23.54M
- Shares outstanding
- 73.55M
- Final 52-week range
- $0.16 – $1.03
- Avg. volume (final 3 mo.)
- 206,964
- All-time high (split-adj.)
- $18.01 · Mar 2019
- All-time low (split-adj.)
- $0.18 · May 2022
- Return since IPO
- -97.3%
- Beta
- 1.46
- Book value / share
- -$0.76
- Price / book
- -0.42
Stealth BioTherapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $0.00 | -$52.5M | -$0.10 |
| FY2020 | $0.00 | -$57.5M | -$0.05 |
| FY2019 | $21.09M | -$71.7M | -$0.26 |
| FY2018 | $0.00 | -$96.7M | — |
| FY2017 | $0.00 | -$82.9M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Stealth BioTherapeutics Corp
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.
Stealth BioTherapeutics stock FAQ
What happened to Stealth BioTherapeutics stock?
Stealth BioTherapeutics stock was delisted from the Nasdaq. Its final close was $0.32 on November 15, 2022.
Is MITO stock still trading?
No. MITO was delisted from the Nasdaq in November 2022 and no longer trades on a U.S. exchange.
What was the last price of MITO stock?
MITO closed at $0.32 on its final trading day, November 15, 2022, for a market value of about $23.54M.
What were Stealth BioTherapeutics's revenue and earnings in its last full fiscal year?
Stealth BioTherapeutics reported revenue of $0.00 and net income of -$52.5M in fiscal 2021, its last full year as a public company.
When did Stealth BioTherapeutics go public?
Stealth BioTherapeutics Corp stock began trading on February 15, 2019.